Revolutionizing Methylation Analysis: NEB Launches EM-seq™ v2
Revolutionizing Methylation Analysis: EM-seq™ v2
The updated EM-seq™ v2 offers a bisulfite-free method for methylation detection that has been optimized for performance. With its new workflow, researchers can achieve highly sensitive analysis of methylation markers like 5mC and 5hmC using only 100 picograms of input DNA.
Key Features of EM-seq™ v2
New England Biolabs (NEB) has introduced this advanced enzyme-based alternative to traditional bisulfite sequencing. The original EM-seq kit faced several challenges and limitations, including DNA damage and fragmentation during the bisulfite treatment. EM-seq v2 addresses these issues, providing a solution that delivers better efficiency, accuracy, and reliability for researchers.
Improved Input Requirements
One of the most significant improvements of the EM-seq v2 is the reduction in minimum DNA input from 10 nanograms to just 100 picograms. This change allows researchers with limited sample availability or those working with precious samples to conduct their methylation studies effectively.
Streamlined Workflow Enhancements
The updated kit also features a streamlined workflow that saves researchers approximately 30 to 45 minutes, thanks to an accelerated incubation step and the elimination of a cleanup step. This improvement allows for faster processing times, making it easier to manage multiple samples.
Performance Benefits
EM-seq v2 not only speeds up the workflow but also enhances data quality. The kit offers greater mapping efficiency and more even GC coverage, enabling the detection of more CpG sites with fewer sequence reads. These advancements significantly improve the quality of data produced, which is vital for accurate methylation analysis.
Insights from Experts
Andrew Barry, Associate Director of Product Portfolio Management for NEB, emphasized the kit's importance for clinical and epigenetics research. He noted that the enhanced data quality from lower input samples allows researchers to gain more insights while minimizing the amount of sequencing required. This innovation is particularly beneficial for studies focusing on samples that would typically be too low in quantity for traditional methods.
Compatibility and Flexibility
EM-seq v2 is compatible with automation, allowing for easy scale-up of experiments. It also supports the 5hmC-seq method specifically for detecting 5-hydroxymethylcytosine, offering researchers heightened flexibility in their experimental designs. Additionally, indexing primers are now supplied separately, enhancing the multiplexing capabilities of the kit.
Ongoing Commitment to Quality
NEB's commitment to quality is evident in the feedback from customers like Dr. Marta Gut, Head of the Sequencing Unit at CNAG. After testing the NEBNext Enzymatic Methyl-Seq v2, her team determined that EM-seq v2 has become their preferred method for studying methylation modifications. The ability to rely on the consistency and reproducibility of NEB's kits has proven invaluable in their research efforts.
While NEB continues to innovate with the EM-seq v2, the original EM-seq kit remains available, ensuring researchers have options that suit their specific needs. For thorough performance data and additional information on these groundbreaking products, more details can be found on NEB's website.
About New England Biolabs
New England Biolabs (NEB) has been a pioneer in molecular biology research for over 50 years, contributing to the development of innovative products tailored for scientific advancement. With a robust product portfolio that evolves with the latest technologies, NEB supports research in both academia and industry, including applications in molecular diagnostics and nucleic acids development.
Headquartered in Ipswich, MA, NEB operates globally, driven by a commitment to scientific discovery and community well-being. The company invests in research that drives innovation and development in a variety of fields, highlighting its dedication to future advancements in biology.
Frequently Asked Questions
What is EM-seq™ v2?
EM-seq™ v2 is an advanced enzyme-based method designed by New England Biolabs for detecting methylation markers like 5mC and 5hmC, replacing traditional bisulfite sequencing.
How does EM-seq™ v2 improve upon the original kit?
The updated version reduces the DNA input requirement, streamlines the workflow, and enhances data quality, allowing for better performance with limited samples.
Who can benefit from using EM-seq™ v2?
Researchers in clinical and epigenetics studies will find EM-seq™ v2 particularly useful, especially when working with low input samples that are challenging to analyze with conventional methods.
What advancements ensure better data quality with EM-seq™ v2?
Key improvements include greater mapping efficiency and even GC coverage, enabling the detection of more CpG sites with fewer sequence reads.
Is the original EM-seq kit still available?
Yes, the original EM-seq kit remains available alongside the new EM-seq™ v2, providing researchers with choices for their methylation studies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.